We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-1.96%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$114M
AUM Growth
-$29.8M
Cap. Flow
-$27M
Cap. Flow %
-23.68%
Top 10 Hldgs %
42.25%
Holding
85
New
11
Increased
13
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.51M
2
IBB icon
iShares Biotechnology ETF
IBB
+$2.38M
3
BPMC
Blueprint Medicines
BPMC
+$2.19M
4
CDTX
Cidara Therapeutics
CDTX
+$1.66M
5
ADXS
Advaxis Inc
ADXS
+$1.57M

Top Sells

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$15M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$9.26M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.15M
4
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.81M
5
TSRO
TESARO, Inc.
TSRO
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$1.66M 1.46%
+7,996
New +$1.66M
SPNC
27
DELISTED
Spectranetics Corp
SPNC
$1.6M 1.41%
65,496
– –
TNDM icon
28
Tandem Diabetes Care
TNDM
$1.22B
$1.56M 1.37%
72,429
– –
SYRE icon
29
Spyre Therapeutics
SYRE
$8.68B
$1.52M 1.34%
14,016
– –
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$343M
$1.45M 1.27%
59,284
-25
-0% -$713
ADXS
31
DELISTED
Advaxis Inc
ADXS
$1.25M 1.1%
+11,667
New +$1.57M
QURE icon
32
uniQure
QURE
$2.52B
$1.14M 1%
203,907
– –
JNJ icon
33
Johnson & Johnson
JNJ
$643B
$1.08M 0.95%
9,400
– –
ASND icon
34
Ascendis Pharma A/S
ASND
$16.7B
$1.07M 0.94%
53,000
+22,250
+72% +$444K
PTGX icon
35
Protagonist Therapeutics
PTGX
$8.8B
$1M 0.88%
45,586
-78,218
-63% -$1.74M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$906K 0.8%
74,538
-5,000
-6% -$54.9K
STXS icon
37
Stereotaxis
STXS
$128M
$892K 0.78%
1,372,862
– –
EXAC
38
DELISTED
Exactech Inc
EXAC
$864K 0.76%
31,636
– –
ARQL
39
DELISTED
Arqule Inc
ARQL
$843K 0.74%
+668,735
New +$934K
NDRM
40
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$842K 0.74%
37,921
+23,500
+163% +$440K
ACHN
41
DELISTED
Achillion Pharmaceuticals
ACHN
$812K 0.71%
196,500
+10,000
+5% +$53.2K
NVDQ
42
DELISTED
Novadaq Technologies Inc.
NVDQ
$722K 0.63%
101,841
– –
ELOS
43
DELISTED
Syneron Medical Ltd
ELOS
$722K 0.63%
85,947
– –
CGNT
44
DELISTED
Cogentix Medical, Inc.
CGNT
$710K 0.62%
353,482
– –
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$689K 0.61%
66,968
– –
MASI
46
DELISTED
Masimo
MASI
$674K 0.59%
10,000
– –
ABUS icon
47
Arbutus Biopharma
ABUS
$871M
$573K 0.5%
+234,000
New +$681K
BLUE
48
DELISTED
bluebird bio
BLUE
$555K 0.49%
695
+232
+50% +$184K
SCYX icon
49
SCYNEXIS
SCYX
$36M
$554K 0.49%
2,171
-495
-19% -$145K
EIGR
50
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$468K 0.41%
1,340
-1,660
-55% -$608K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, DAFNA Capital Management held 85 positions worth $114M, down 21% from $144M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

DAFNA Capital Management withdrew a net $27M in Q4 2016, closing 19 positions and reducing 16 holdings. Its most notable exit was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 68% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Viracta Therapeutics, Inc. Common Stock worth $4.1M.

  • DAFNA Capital Management's largest Q4 2016 buy was Viracta Therapeutics, Inc. Common Stock: 32,388 shares worth $4.1M.
  • DAFNA Capital Management added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.45M increase.
  • DAFNA Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $1.77M.
  • DAFNA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2016, selling an estimated $15M.
  • DAFNA Capital Management's ten largest holdings make up 42% of its $114M portfolio in Q4 2016.
  • DAFNA Capital Management opened 11 new positions and closed 19 in Q4 2016.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $114M.

Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.